Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company’s Development in Online and Offline MacroHealth Business

HONG KONG, April 1, 2015 /PRNewswire/ — Jintian Pharmaceutical Group Limited (“Jintian Pharmaceutical” or the “Company”; stock code: 2211) announced that Mr. Jin Dongtao, chairman and executive director purchased 40,000,000 ordinary shares (the “shares”) of the Company, representing 2% of the existing entire issued share capital of the Company from AMG Holdings Limited, at HK$2.82 per share with the total amount of approximately HK$113 million. Upon the completion of the transaction, Mr. Jin Dongtao’s shareholding will increase from 45.17% to 47.17%.

Mr. Jin Dongtao, chairman and executive director and 2014 Annual Results Announcements

Mr. Jin Dongtao, chairman and executive director and 2014 Annual Results Announcements

Mr. Jin Dongtao, with over 20 years’ experience of pharmaceutical industry, enjoying great influence in China’s pharmaceuticals industry. In addition to focus on the Company’s business development, as the leader of the Group, Mr. Jin Dongtao also pays close attention to the market and industry trend, actively promotes the industry concept of MacroHealth (Holistic wellness which includes healthcare and medical industry), develops the market of e-commerce, aiming at building up Jintian Pharmaceutical into a leader in international MacroHealth brand management.

Mr. Jin Dongtao’s explanation of the increase of shareholding will better interpret the Company’s strategic conception:

First, Mr. Jin Dongtao has great confidence in the development of China’s MacroHealth industry.

With China entering aging society, MacroHealth industry, strongly supported by the nation, enjoys huge development potential. Jintian Pharmaceutical, as the forerunner in the pharmaceutical distribution industry, takes the lead in implementing layout of MacroHealth industry with its extraordinary healthcare entity network.

Second, Mr. Jin Dongtao has great confidence in the development of cross-border trading.

By the international perspective resulted from listing in Hong Kong, on one hand, through distributing and selling international MacroHealth brands’ products, the Company achieved strategic cooperation with multiple world-renowned manufactures, expanded the market for the products, and improved profitability and competitiveness among domestic peers; on the other hand, the Company follows closely with the development of free trade zones in China and arrange its business accordingly, in the future the Company will enter the international market to cooperate with famous enterprises from Asia and even from Europe and the United States, so as to establish overseas MacroHealth brand operation and management enterprise.

Third, Mr. Jin Dongtao has great confidence in the establishment of mobile internet platforms.

The Chinese government revealed “Internet Plus” strategy recently, which brought huge development potential for the industry. During 2014, after cooperation with Ali Health, the Company introduced elite teams from the Internet field to actively develop retail and distribution network, and to establish competitive O2O platform. The Company combines with advantages of its entity network to promote fast implementation of our e-commerce strategy to best leverage our leading real economy advantage. The Golden Rules of Marketing and professional training of Jintian Institute make contribution to promoting the Company’s high-margin products. In the meantime, under the thinking mode of platform cooperation, the Company established crossover in e-commerce business in a great extent and depth with dozens of MacroHealth industry-related enterprises at home and abroad.

Mr. Jin Dongtao mentioned, “CVC Capital Partners, as one of our main pre-ipo private fund investors, their lock-up period has expired after three and a half years’ holding period. This transaction is a win-win investment decision. The Company and I maintain a good relationship with CVC. We hereby gratitude to CVC for their years of support.”

Strong FY14 Results. MS maintain their Valuation “Attractive”

In 2014, the revenue and gross profit of the Group increased by 31.1% and 35.4% respectively as compared with 2013. Over gross profit margin increased to 29.1%. Earnings per share for the Reporting Period was RMB23.77 cents.

As at 31 December 2014, the Group acquired 157 retail pharmacies and opened 2 new retail pharmacies. The Group had 953 self-operated pharmacies in total, of which 4 are located in Hong Kong. The Group has established a nationwide distribution network covering approximately 6,500 customers. Meanwhile, the Group now has a total of six logistics centres in Shijiazhuang, Harbin, Jiamusi and other places, which further strengthened our advantages of nationwide distribution network. During the Reporting Period, the Group cooperated with Alibaba Health to launch online prescription drug business in Northeast China.

The Group has high net profit margin which benefits from the focus on branded premium products portfolio, the unique direct supply model, central procurement platform and low operating costs. Jintian Training Institute provides professional training service to employees and customers representing strong abilities of execution and acquisitions integration. In this way, the product portfolio and advanced business model can be applied into the acquisition business. The Group has established a unique business model and strong core competitiveness. In addition, e-commerce and mobile Internet services and MacroHealth has been brought into the Group’s strategy.

Based on FY14 results, Morgan Stanley maintains their bear-case valuation of “Attractive”. And they expect the price target can be HK$4.50 and the stock will bullish on the Group’s accelerating sales growth through offline distribution and retail channels and online platforms.

About JINTIAN PHARMACEUTICAL GROUP LIMITED

Jintian Pharmaceutical Group Limited (“Jintian Pharmaceutical” or the “Company”, stock code: 2211) is one of the leading pharmaceutical retailers and distributors in China, and certified as the Top 10 of 2013-2014 China chain pharmacy stores by the State Food and Drug administration. As at 31 December 2014, the Company has 953 retail pharmacies in including four stores in Hong Kong and approximately 6,500 distribution customers. The Company has high net profit margin, which is attributable to the product mix with a focus on high-gross-margin products, the effective direct-supply model, the centralized procurement platform and low operation costs. The Company provides training programs to its employees and customers through Jintian Institute. The Company also has strong execution capability for acquisitions and integration which enables it to implement its product mix, advanced business model and sophisticated operation procedures in the acquired businesses. The Company has formed distinctive business model and core competitive strengths.

This press release is issued by Wonderful Sky Financial Group Holdings Limited on behalf of JINTIAN PHARMACEUTICAL GROUP LIMITED.

For further information, please contact:

Wonderful Sky Financial Group Holdings Limited
Connie Liu / Angus Song / Sylvia Zhang
Tel: (852) 3970 2290 / (852) 3970 2175 / (852) 3970 2161  
Fax: (852) 2598 1588
Email: po@wsfg.hk / angussong@wsfg.hk / sylviazhang@wsfg.hk

Photo – http://photos.prnasia.com/prnh/20150401/8521502085

Continue Reading

Tian Ge Becomes a Constituent of Hang Seng Composite Index, Hang Seng Global Composite Index and Hang Seng Broad Consumption Index

HONG KONG and HANGZHOU, China, March 3, 2015 /PRNewswire/ — Tian Ge Interactive Holdings Limited (“Tian Ge” or the “Company”, 1980.HK), the largest “many-to-many” live social communities platform in China, is pleased to announce that the Company has recently been included by Hang Seng Indexes Company Limited as a constitute of the Hang Seng Composite Index (“HSCI”) series, including the Hang Seng Composite Index, The Hang Seng Composite SmallCap Index, The Hang Seng Composite Industrial Index – Information Technology, Hang Seng Global Composite Index (“HSGCI”), as well as the Hang Seng Broad Consumption Index (“HSBCI”), with effect from 9 March 2015 (Monday).

In November 2014, Tian Ge has also been included as a constituent of the Morgan Stanley Capital International (“MSCI”) Global Small Cap Indexes – China Index. MSCI is a leading provider of global equity indices and benchmark related products and services to investors worldwide.

HSCI, HSGCI and HSBCI are managed by Hang Seng Indexes Company Limited. A review is conducted every half-year. More details are available on http://www.hsi.com.hk/HSI-Net/HSI-Net.

– End –

About Tian Ge

Tian Ge (1980.HK) is one of the largest live social online video community platforms in China. The Company was founded in Hangzhou, China in 2008 and went public on the main board of the stock exchange of Hong Kong in July 2014. It currently operate eight “many-to-many” live social video communities on both mobile and PC, including 9158 and Sina Show, the two largest communities; and one “one-to-many” community, Sina Showcase.

Our communities offer diverse selection of user-generated content in the live social online video community industry. Through our “many-to-many” ecosystem where multiple users can simultaneously stream to other viewers in the same real-time video room, Tian Ge enables users to interact, socialize, share interest, send virtual items & gifts, and encourages our users to showcase their talents or knowledge for open and public exposure. Recently, we expanded our ecosystem to the online-to-offline (O2O) karaoke, live social mobile & PC games and emerging healthcare mobile application.

For more information, please visit www.tiange.com

To visit our communities:
9158: www.9158.com; Sina Show: http://show.sina.com.cn/; Sina Showcase: http://ok.sina.com.cn/

For media inquiries, please feel free to contact:

LBS Communications Consulting Limited
Joanne Chan (852-9616 2676), Janice Liu (852-9859 0513), Ian Fok (852-9348 4484)
Tel : (852) 3679 3671 / (852) 3752 0428 / (852) 3752 0432
Fax : (852) 3753 2899
Email: jchan@lbs-comm.com / jliu@lbs-comm.com / ifok@lbs-comm.com

For investor inquiries, please contact:

Kenneth Ke
Tel: +86 (571) 88108686 Ext. 8103
Email: kenneth@9158.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tian-ge-becomes-a-constituent-of-hang-seng-composite-index-hang-seng-global-composite-index-and-hang-seng-broad-consumption-index-300044290.html

Continue Reading

Low-cost, Sustainable Innovations Gain Traction in Africa, Finds Frost & Sullivan

— Product and process innovations in the ICT sector have boosted the continent’s economic performance

CAPE TOWN, South Africa, Feb. 5, 2015 /PRNewswire/ — As the second largest continent in the world, and having the second highest population after Asia, Africa is a lucrative destination for innovation activities. The extended period of political stability and favourable demographic dividend has attracted billions of dollars in foreign direct investment across various sectors. Still, substantial space exists for faster innovations instead of long-term development projects.

New analysis from Frost & Sullivan, Innovations in Emerging Economies – Africa, finds that Africa is a hub for innovation in the automation and electronics, information and communication technologies (ICT), healthcare, chemicals and materials, and energy and environment sectors.

For complimentary access to more information on this research, please visit: http://ow.ly/IsAnc.

“Innovations in the ICT sector in Africa have been of considerable importance in making the continent one of the most promising emerging economies across the globe,” noted Technical Insights Research Analyst  Debarun Guha Thakurta. “Apart from product innovations driven by Mega Trends, several process innovations in the ICT domain, such as digital payments, e-health and e-commerce, have enabled the continent to progress quickly.”

In the ICT sector, innovations that improve the governance and lifestyle of Africans to spread technology awareness through enhanced connectivity have been opening up economic opportunities. For instance, ICT-enabled financial services that widen the reach of banks have led to the development of new business models that leverage the flexibility of e-finance.

Through the use of local and foreign aid, the healthcare industry has also engaged in widespread innovation activity. Locally, innovations have focussed on the development of cheaper and sustainable devices and services, while global funding has focused on research and development (R&D) and heavy infrastructure development. Healthcare players across Africa have demonstrated particular interest in malaria treatment and vaccination, HIV/AIDS research, effective distribution of drugs and devices, and long-term investments in hospitals, research centres and educational institutes.

Much like the healthcare sector, the focus in the materials and coatings, as well as automation and electronics sectors, has revolved around the development of low-cost, sustainable solutions. However, the lack of a technology innovation culture in Africa compared to other parts of the world has slowed down the pace of innovation across these sectors. As such, the region needs to promote innovation at the university level to remain on par with their global counterparts.

The lack of access to funding has been another obstacle to technological innovation in Africa. As countries devote most of the available funding towards tackling poverty and providing basic resources to the population, there is limited financial support for technological activities. This, along with high levels of corruption, has prevented the continent from reaching its true innovation potential.

“Nevertheless, as low-cost, sustainable innovation gathers pace in Africa, companies across sectors could replicate these best practices in other emerging markets, where there is huge potential for companies to expand,” said Guha Thakurta. “They can also employ reverse innovation, wherein innovations are tested and developed in Africa before being launched in the highly competitive developed markets.”

Innovations in Emerging Economies – Africa, a part of the Technical Insights (http://www.technicalinsights.frost.com) subscription, provides an overview of the key innovations in the healthcare, ICT, materials & coatings, and automation & electronics sectors in Africa. Further, this research service includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on “the next big thing”
Register:         Gain access to visionary innovation

Innovations in Emerging Economies – Africa
D541

Contact:
Samantha James
Corporate Communications – Africa
P: +27 21 680 3574
F: +27 21 680 3296
E: samantha.james@frost.com

http://www.frost.com
http://www.technicalinsights.frost.com

Continue Reading

Diebold, Corning Pioneer World’s First Antimicrobial ATM Touch Screen

NORTH CANTON, Ohio, Jan. 6, 2015 /PRNewswire/ — Diebold, Incorporated (NYSE: DBD) and Corning Incorporated (NYSE: GLW) have teamed up to introduce the first automated teller machine (ATM) touch screen featuring Antimicrobial Corning® Gorilla® Glass. The glass is formulated with an embedded antimicrobial agent, ionic silver, which inhibits the growth of algae, mold, mildew, fungi and bacteria on its surface. The companies will showcase a prototype antimicrobial touch screen on Diebold’s newly released 5500 series ATM in Corning’s booth during the International Consumer Electronics Show (CES), Jan. 6-9, 2015, in Las Vegas.

Logo – http://photos.prnewswire.com/prnh/20080725/DIEBOLDLOGO

“Touched by hundreds of users every day, the ATM is a universal shared touch device,” said Joydeep Lahiri, division vice president and program director, Specialty Surfaces, Corning Incorporated. “Therefore, toughness and antimicrobial protection are desired attributes. For Diebold ATMs, Antimicrobial Corning Gorilla Glass will deliver lifelong antimicrobial activity that won’t compromise toughness or optical clarity.”

Diebold plans to offer Antimicrobial Corning Gorilla Glass as an option on its expanding line of self-service terminals, including the recently launched 5500, 3500, 3700and 9900series ATMs, as well as a retrofit option for existing ATMs.

“Touch screens are found on a growing number of ATMs today. Offering antimicrobial glass on frequently touched surfaces such as the ATM touchscreen will help financial institutions address the concerns of the public,” said Frank A. Natoli, Jr., executive vice president and chief innovation officer, Diebold. “Our innovative collaboration with Corning will help us offer improved durability and antimicrobial function for our next generation of touchscreen ATMs.”

Antimicrobial protection is limited to the glass product itself, and neither Corning nor Diebold makes any direct or implied health claims about the antimicrobial properties of the product.

About Corning Incorporated

Corning (www.corning.com) is one of the world’s leading innovators in materials science. For more than 160 years, Corning has applied its unparalleled expertise in specialty glass, ceramics and optical physics to develop products that have created new industries and transformed people’s lives. Corning succeeds through sustained investment in R&D, a unique combination of material and process innovation, and close collaboration with customers to solve tough technology challenges. Corning’s businesses and markets are constantly evolving. Today, Corning’s products enable diverse industries such as consumer electronics, telecommunications, transportation and life sciences. They include damage-resistant cover glass for smartphones and tablets; precision glass for advanced displays; optical fiber, wireless technologies and connectivity solutions for high-speed communications networks; trusted products that accelerate drug discovery and manufacturing; and emissions-control products for cars, trucks and off-road vehicles.

About Diebold

Diebold, Incorporated (NYSE: DBD) is a global leader in providing innovative self-service technology, security systems and related services. Diebold has approximately 16,000 employees worldwide and is headquartered near Canton, Ohio, USA. Visit Diebold at www.diebold.com or on Twitter: http://twitter.com/DieboldInc.

Continue Reading

China Jo-Jo Drugstores Posted Record Online Sales on “Singles Day China” with 265% Revenue Increase

HANGZHOU, China, November 20, 2014 /PRNewswire/ — China Jo-Jo Drugstores, Inc. (NASDAQ CM: CJJD) (the “Company”), a leading China-based retail and wholesale distributor of pharmaceutical and healthcare products through its own retail and online pharmacies, today announced its online pharmacy posted the largest one-day sales on Singles Day China, or the Black Friday China (“Singles Day”), November 11, 2014 with total revenue increased by 265% year over year, on a one-day sales comparison basis.

In order to encourage online shopping, since 2009, large online retailers in China such as Tmall.com (“Tmall”) of Alibaba Group Holdings (NYSE: BABA), China’s largest B2C online retailer and JD.com (NASDAQ: JD) (“JD”) have started to make various discount sales on November 11 every year. November 11, also called Singles Day, has become the largest online commercial event in China.

Highlights of the Company’s online pharmacy sales on Singles Day include:

  • Total one-day sales revenue reached approximately $521,000 (RMB3.21 million), a 265% increase from the sales record on the same day of the prior year. The result vastly exceeded the Company’s targeted sales goal of approximately $325,000 (RMB2 million). The number of one-day online purchase orders increased 328% over the same day last year. In comparison, our regular daily online sale averaged at approximately $42,000 (RMB 0.26 million) in October 2014, an increase of more than 250% from the same month in 2013.
  • More than 90% of the Company’s online sales were generated from our online pharmacy at Tmall, the Company’s online stores at JD and YHD.com. The Company’s official website generated the remaining sales.
  • As of October 2014, our online pharmacy was ranked 10th on Tmall.com in the Pharmacy and Health Goods category

“We are very encouraged to see a great increase of our online pharmacy sales during the Singles Day online shopping festival this year. We will continue to offer quality and safe products on our e-commerce platform, and provide a better shopping experience to our customers,” commented Mr. Liu, Lei, Chairman and CEO of China Jo-Jo Drugstore. “Looking ahead, the dramatic increase of our online pharmacy sales on Tmall encourages us to further pursue our online growth strategy which we believe to be one of biggest opportunities for us in 2015 and beyond.”

About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its own retail drugstores, wholesale distributor and online pharmacy, is a leading retailer and wholesale distributor of pharmaceutical and healthcare products in China. As of September 30, 2014, the Company had 51 retail pharmacies in Hangzhou. The Company’s wholesale subsidiary not only supplies its retail stores, but also distributes drug and other healthcare products to other drugstores and drug vendors. The Company routinely posts important information on its corporate websites at www.jiuzhou-drugstore.com (Chinese) and www.chinajojodrugstores.com (English).

Forward Looking Statement

Statements in this press release regarding the Company that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including, but not limited to, financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” “anticipate,” the negatives thereof, or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. It is routine for the Company’s internal projections and expectations to change as the quarter and year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which the Company bases its expectations may change. Although these expectations may change, the Company is under no obligation to inform you if they do. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of numerous factors, including the risks associated with the effect of changing economic conditions in the People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products. Readers are referred to the reports and documents filed from time to time by the Company with the Securities and Exchange Commission for a discussion of these and other important risk factors that could cause actual results to differ from those discussed in forward-looking statements.

Contacts

China Jo-Jo Drugstores, Inc.
Ming Zhao
Chief Financial Officer
Tel: (561) 372-5555
Email: frank.zhao@jojodrugstores.com

Continue Reading